İnsani Amaçlı İlaca Erken Erişim Programları

Burç Aydın

Derleme

COMPASSIONATE USE PROGRAMMES OF MEDICINAL PRODUCTS

Yıl 2018, Cilt: 32 Sayı: 3, 237 - 242, 15.12.2018

Burç Aydın

Öz

Compassionate use programs of
medicinal products are intended to provide unauthorized medicines for
humanitarian purposes without a fee for patients with a serious or urgent, life
threatening disease and whom authorized, available medicinal products cannot
treat satisfactorily, and who cannot enter a clinical trial. This review
summarizes regulations on compassionate use programs of medicinal products in
Turkey, European Union, and United States of America and investigates program
practices in Turkey in detail.

Anahtar Kelimeler

Compassionate use of medicinal products, medicine, regulation

Kaynakça

T.C. Resmi Gazete. Beşeri tıbbi ürünler ruhsatlandırma yönetmeliği. 19 Ocak 2005;25705.
T.C. Resmi Gazete. Sağlık hizmetleri temel kanunu. 15 Mayıs 1987;19461.
T.C. Resmi Gazete. İspençiyari ve tıbbi müstahzarlar kanunu. 26 Mayıs 1928;898.
T.C. Resmi Gazete. İlaç ve biyolojik ürünlerin klinik araştırmaları hakkında yönetmelik. 13 Nisan 2013;28617.
Türkiye İlaç ve Tıbbi Cihaz Kurumu. Yurt dışından ilaç temini ve kullanımı kılavuzu. 21 Nisan 2017.
Türkiye İlaç ve Tıbbi Cihaz Kurumu. Endikasyon dışı ilaç kullanımı kılavuzu. 3 Mayıs 2016.
Türkiye İlaç ve Tıbbi Cihaz Kurumu. İnsani amaçlı ilaca erken erişim programı kılavuzu. 1 Ocak 2009.
Darrow JJ, Sarpatwari A, Avorn J, Kesselheim AS. Practical, legal, and ethical issues in expanded access to investigational drugs. N Engl J Med 2015; 372: 279-86.
Iudicello A, Alberghini L, Benini G, Mosconi P. Expanded Access Programme: looking for a common definition. Trials 2016; 17: 21.
Whitfield K, Huemer KH, Winter D, et al. Compassionate use of interventions: results of a European Clinical Research Infrastructures Network (ECRIN) survey of ten European countries. Trials 2010; 11: 104.
European Parliament and Council of the European Union. Regulation (EC) No 726/2004 of the European Parliament and of the Council. Official Journal of the European Union L 136, 30.4.2004, 1–33.
European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on Compassionate Use of Medicinal Products, Pursuant to Article 83 of Regulation (EC) No 726/2004. EMEA/27170/2006, 19 July 2007.
European Medicines Agency. Launch of PRIME – Paving the way for promising medicines for patients. EMA/89921/2016, 4 March 2016.
Food and Drug Administration, Department of Health and Human Services. Expanded access to investigational drugs for treatment use. 21 CFR part 312, subpart I, August 13, 2009.
Food and Drug Administration, Department of Health and Human Services. Individual patient expanded access applications: Form FDA 3926. Guidance for industry. June 2016. .
European Parliament and Council of the European Union. Directive 2001/83/EC of the European Parliament and of the Council. Official Journal of the European Union L 311, 28.11.2001, 67-128.
T.C. Resmi Gazete. Beşerî tıbbi ürünlerin tanıtım faaliyetleri hakkında yönetmelik. 3 Temmuz 2015;29405.
Capello E, Gardella M, Leandri M, Abbruzzese G, Minatel C, Tartaglione A, et al. Lowering body temperature with a cooling süit as symptomatic treatment for thermosensitivite multiple sclerosis patients. Ital J Neurol Sci 1995;16:533-539.
Andreasen AK, Stenager E, Dalgas U. The effect of exercise therapy on fatigue in multiple sclerosis. J Mult Scler 2011;1-14.
White AT, Wilson TE, Davis SL, Petejan JH. Effect of Cooling on Physical Performance in Multiple Sclerosis. Mult Scler 2000;6:176-180.
Henze T. What is new in symptom management? Int MS J 2007;14:22–27.
Akkus Y. Multiple Sklerozlu Hastalarda Ev Ziyareti Yoluyla Verilen Bakım Hizmetinin Yaşam Kalitesine Etkisi, Doktora Tezi, Hacettepe Üniversitesi Sağlık Bilimleri Enstitüsü 2008, Ankara.
Tülek Z. Multiple Sklerozlu hastanın hemşirelik bakımı. C.Ü. Hemşirelik Yüksekokulu Dergisi 2007;11:25-32.